FDA Approves High-Dose Regimen of Nusinersen for Spinal Muscular Atrophy Biogen announced that the FDA has approved a high-dose regimen of nusinersen for the treatment of SMA in pediatric and adult patients.

The @fda.gov has approved a high-dose regimen of #Nusinersen (#Spinraza®) for the treatment of spinal muscular atrophy (#SMA) in pediatric and adult patients, Biogen announced.

Learn more: https://bit.ly/4s7yn8e

#RareDisease #SpinalMuscularAtrophy #MedSky

FDA Grants Approval for High Dose SPINRAZA to Benefit SMA Patients Cure SMA celebrates the FDA's approval of Biogen's High Dose SPINRAZA regimen, providing hope and improved care for individuals living with SMA.

FDA Grants Approval for High Dose SPINRAZA to Benefit SMA Patients #USA #SMA #Schaumburg #Cure_SMA #SPINRAZA

バイオジェン、ヌシネルセン高用量がNature Medicine掲載──SMAでCHOP-INTEND有意改善、米PDUFAは2026年4月3日 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究

Biogen’s high-dose nusinersen published in Nature Medicine; DEVOTE shows significant CHOP-INTEND improvement in SMA

stellanews.life/technology/8...

#SMA #Nusinersen #SPINRAZA #DEVOTE #CHOPINTEND #FDA #PDUFA

Read about high-dose Spinraza study results—find out more here: https://bit.ly/3ZzUh8X

#SMA #Spinraza #DEVOTE #SMANews #Bionews

What the EC Decision on High-Dose Spinraza Means for SMA Care | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.

🧬 EC approves high-dose Spinraza for #SMA 🇪🇺
Backed by DEVOTE & RESPOND data, the new nusinersen regimen delivers higher exposure earlier, supporting stronger motor neuron preservation and meaningful clinical gains 💙

Read more 👉 www.neurologylive.com/view/reactio...
#Spinraza #Neurology

📣High-Dose Regimen of nusinersen receives EC Approval for the treatment of SMA. investors.biogen.com/news-releases/news-relea...

#spinalmuscularatrophy #spinraza #accesstotreatment

A big part of #Biogen's efforts to defend its #spinalmuscularatrophy (SMA) business has been dealt a setback by the FDA, which declined to approve a high-dose version of its flagship #Spinraza product.

pharmaphorum.com/news/fda-kno...

Original post on pol.social

No i kolejne świetne rozwiązanie dla #AI znalezione.
Właśnie leżę w łóżku ze względu na ból pleców po wczorajszym podaniu leku #Spinraza. Przyszło mi do głowy parę fajnych pomysłów do zaprogramowania, ale ze względu na to, że leżąc naprawdę bardzo źle mi się pisze, nawet na klawiaturze ekranowej […]

Ultra Rare Disease Drug Development — DNA Today Biotech titan Dr. Stan Crooke, who developed 20+ drugs, shares about his new n-Lorem Foundation designing drugs for ultra rare disease patients. All in this 30 minute video and audio podcast episode…

August is #spinalmuscularatrophy awareness month 💜

#Spinraza is a life changing drug for SMA, a pharmacist behind the drug development, @n_lorem’s Dr. Crooke explains on our #sciencepodcast 💉

Adrian Krainer wins 2025 Heinrich Wieland Prize | Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory Professor Adrian Krainer has won the 2025 Heinrich Wieland Prize. Awarded annually by the Boehringer Ingelheim Foundation, the €250,000 prize recognizes exceptional scien...

CSHL’s Adrian Krainer has won the 2025 Heinrich Wieland Prize for his groundbreaking RNA research and the development of Spinraza—a lifesaving SMA treatment. Congrats, Dr. Krainer! www.cshl.edu/adrian-krain...
#CSHL #RNAresearch #Spinraza #SMA

#RightToTry panel: @ErinPaquetteMD @NorthwesternMed @LurieChildrens @LuriePICU discusses the case study of #nusinersin #Spinraza for #SMA (spinal muscular atrophy) #HLP19 #HealthLawRocks